CA2744231A1 - Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol - Google Patents

Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol Download PDF

Info

Publication number
CA2744231A1
CA2744231A1 CA2744231A CA2744231A CA2744231A1 CA 2744231 A1 CA2744231 A1 CA 2744231A1 CA 2744231 A CA2744231 A CA 2744231A CA 2744231 A CA2744231 A CA 2744231A CA 2744231 A1 CA2744231 A1 CA 2744231A1
Authority
CA
Canada
Prior art keywords
species
oxaborol
propoxy
benzo
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744231A
Other languages
English (en)
French (fr)
Inventor
Conrad Wheeler
Dan Todd
Pingyun Chen
Beth A. Norton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Anacor Pharmaceuticals LLC
Original Assignee
GlaxoSmithKline LLC
Anacor Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC, Anacor Pharmaceuticals LLC filed Critical GlaxoSmithKline LLC
Publication of CA2744231A1 publication Critical patent/CA2744231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2744231A 2008-12-17 2009-12-17 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol Abandoned CA2744231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13849008P 2008-12-17 2008-12-17
US61/138,490 2008-12-17
PCT/US2009/068609 WO2010080558A1 (en) 2008-12-17 2009-12-17 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol

Publications (1)

Publication Number Publication Date
CA2744231A1 true CA2744231A1 (en) 2010-07-15

Family

ID=42316734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744231A Abandoned CA2744231A1 (en) 2008-12-17 2009-12-17 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol

Country Status (18)

Country Link
US (1) US8461364B2 (cg-RX-API-DMAC7.html)
EP (1) EP2378886A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012512262A (cg-RX-API-DMAC7.html)
KR (1) KR20110111407A (cg-RX-API-DMAC7.html)
CN (1) CN102256494A (cg-RX-API-DMAC7.html)
AU (1) AU2009335744A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922566A2 (cg-RX-API-DMAC7.html)
CA (1) CA2744231A1 (cg-RX-API-DMAC7.html)
CO (1) CO6390029A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110357A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000183A (cg-RX-API-DMAC7.html)
EA (1) EA201190034A1 (cg-RX-API-DMAC7.html)
IL (1) IL213060A0 (cg-RX-API-DMAC7.html)
MA (1) MA32977B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006334A (cg-RX-API-DMAC7.html)
PE (1) PE20120052A1 (cg-RX-API-DMAC7.html)
SG (1) SG172040A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010080558A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976536A4 (en) 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc SMALL MOLECULES CONTAINING BORON
KR20150013941A (ko) 2006-02-16 2015-02-05 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN103180328B (zh) * 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
CA2810021C (en) * 2010-09-07 2018-05-29 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP6031122B2 (ja) * 2011-12-22 2016-11-24 ミクウルク ファーマシューティカルズ，インコーポレイテッド 抗微生物療法のための三環式ホウ素化合物
PL2950644T3 (pl) 2013-01-30 2017-10-31 Agrofresh Inc Stosowanie benzoksaboroli jako lotnych środków przeciwbakteryjnych na mięsach, roślinach lub częściach roślinnych
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2014121124A1 (en) 2013-02-01 2014-08-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
CA2919888C (en) 2013-08-09 2022-10-18 Anacor Pharmaceuticals, Inc. Tricyclic benzoxaborole compounds and uses thereof
TW201625649A (zh) 2014-07-01 2016-07-16 第一三共股份有限公司 作爲抗菌劑的三環化合物
MA41494B1 (fr) 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
TW201735792A (zh) 2016-03-07 2017-10-16 農業保鮮股份有限公司 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
EP3609504A4 (en) 2017-03-01 2021-03-03 Anacor Pharmaceuticals, Inc. NEW OXABOROLE ANALOGUES AND USES OF THE LATEST
WO2022043936A1 (en) 2020-08-31 2022-03-03 Pfizer Inc. Methods of protecting rna
US12228578B2 (en) 2020-12-17 2025-02-18 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
GB1396904A (en) 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP2223920A3 (en) 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6413751B1 (en) 1996-09-19 2002-07-02 The Board Of Trustees Of The Leland Stanford Jr. University DNA adenine methyltransferases and uses thereof
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
EP1155698A4 (en) 1999-01-29 2003-01-15 Nitto Kasei Co Ltd ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
CA2373279A1 (en) 1999-05-25 2000-12-14 The Penn State Research Foundation Dna methyltransferase inhibitors
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
EP1303625A2 (en) 2000-07-14 2003-04-23 Zycos Inc. Alpha-msh related compounds and methods of use
ATE346074T1 (de) 2000-11-30 2006-12-15 Penn State Res Found Dna methyl transferase inhibitoren
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
EP1444981A1 (en) 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
US7405304B2 (en) 2002-01-10 2008-07-29 The Penn State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
EP1581500A4 (en) 2002-12-18 2008-03-05 Anacor Pharmaceuticals Inc ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE
US20050125852A1 (en) 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
MXPA05013848A (es) 2003-06-16 2006-09-04 Anacor Pharmaceuticals Inc Agentes terapeuticos que contienen boro hidroliticamente resistentes y metodos de uso.
KR101300929B1 (ko) 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
WO2006062731A1 (en) 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
KR101337045B1 (ko) 2005-02-16 2013-12-05 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
US20060251689A1 (en) 2005-03-30 2006-11-09 Astion Development A/S Treatment or prevention of pruritus
US20080234229A1 (en) 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
EP1976536A4 (en) 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc SMALL MOLECULES CONTAINING BORON
KR20150013941A (ko) 2006-02-16 2015-02-05 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
RU2008152367A (ru) 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents

Also Published As

Publication number Publication date
SG172040A1 (en) 2011-07-28
CN102256494A (zh) 2011-11-23
US20110152217A1 (en) 2011-06-23
KR20110111407A (ko) 2011-10-11
JP2012512262A (ja) 2012-05-31
US8461364B2 (en) 2013-06-11
EP2378886A1 (en) 2011-10-26
CR20110357A (es) 2011-11-11
CO6390029A2 (es) 2012-02-29
EP2378886A4 (en) 2012-08-29
MX2011006334A (es) 2011-09-22
MA32977B1 (fr) 2012-01-02
AU2009335744A1 (en) 2010-07-15
WO2010080558A1 (en) 2010-07-15
DOP2011000183A (es) 2011-07-15
PE20120052A1 (es) 2012-02-13
IL213060A0 (en) 2011-07-31
BRPI0922566A2 (pt) 2017-03-28
EA201190034A1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
US8461364B2 (en) Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
TWI874490B (zh) 三苯化合物之新穎鹽類
AU2015237744A1 (en) Ibrutinib solid forms and production process therefor
CA3073936A1 (en) Ribociclib salts and solid state forms thereof
WO2016011195A1 (en) Th-302 solid forms and methods related thereto
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
TW202124373A (zh) 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
EP3471734B1 (en) Solid state forms of ixazomib citrate
TW202440575A (zh) 一類三環類化合物及其製備和應用
JP2020200300A (ja) エルデカルシトールの新規な結晶形およびその調製方法、および使用に関する
TWI717859B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
KR20120053027A (ko) 페소테로딘 푸마레이트 및 페소테로딘 염기의 결정형
US20080051435A1 (en) Crystalline and amorphous forms of tiagabine
TW202208325A (zh) （Ｒ）—羥布托尼（Ｏｘｙｂｕｔｙｎｉｎ）鹽酸鹽之多晶形式
US20240239791A1 (en) Processes for the synthesis of valbenazine
WO2008021518A2 (en) Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride
US11964993B2 (en) Crystalline bortezomib process
TW202404973A (zh) Ｎ—甲基—Ｎ—（（１Ｓ，３Ｓ）—３—甲基—３—（（６—（１—甲基—１Ｈ—吡唑—４—基）吡唑并［１，５—ａ］吡嗪—４—基）氧基）環丁基）丙烯醯胺之結晶多形體
WO2023061372A1 (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
WO2023143321A1 (zh) 他伐帕敦的晶型及其制备方法和用途
TW202440125A (zh) 水解磷脂酸合成脢抑制劑化合物的新穎晶形
WO2025149547A1 (en) New solid forms of n-[(1s,2e)-1-cyclopropyl-3-(methanesulfonyl)prop-2-en-1-yl]-2- (1,1-difluoroethyl)-4- phenoxypyrimidine-5-carboxamide
CN117480170A (zh) 用于合成缬苯那嗪的方法
BR112019005450B1 (pt) Polimorfos cristalinos de um agonista do receptor de acetilcolina muscarínico, processos para preparar tais polimorfos, processo para manter estável um Forma II do polimorfo, composição farmacêutica, processo para preparar medicamento e uso de tais polimorfos

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141217